Targeting the interactome of the sodium iodide symporter to increase radioiodide uptake in differentiated thyroid cancer

Thornton, Caitlin E. M. (2021). Targeting the interactome of the sodium iodide symporter to increase radioiodide uptake in differentiated thyroid cancer. University of Birmingham. Ph.D.

[img] Thornton2021PhD.pdf
Text - Accepted Version
Restricted to Repository staff only until 1 July 2024.
Available under License All rights reserved.

Download (6MB) | Request a copy

Abstract

Currently, the treatment of differentiated thyroid cancer combines surgical resection of the tumour and thyroid with post-surgical radioiodide therapy to ablate remaining cancer cells. Patients may be refractory to radioiodide treatment due to dysregulated expression of the Na\(^+\)/I\(^-\) symporter (NIS) or its transport to the plasma membrane of thyroid cancer cells. Although some studies have achieved increased expression of NIS, mislocalisation of the protein inside the cell remains common in thyroid tumours. This has led to recent studies exploring the post-translational processing of NIS, which have revealed therapeutic opportunities for targeting NIS-interacting proteins to modulate radioiodide uptake.

This thesis appraised the established NIS interactor valosin-containing protein (VCP), as well as two new binding partners – moesin and annexin A1. Novel strategies for targeting VCP using the inhibitors CB-5083 and CB-5339 resulted in an increase in radioiodide uptake across multiple cellular models. Clotrimazole, which has previously been used as a VCP inhibitor but has limited in vivo utility due to its low bioavailability, was chemically modified. Structural analogues of clotrimazole demonstrated moderately improved effects on iodide uptake and improved bioavailability compared to the parent compound. The putative NIS interactors moesin and annexin A1 were shown to bind NIS via NanoBiT technology and to modulate its iodide uptake function, providing two entirely novel potential therapeutic targets in radioiodide refractory differentiated thyroid cancer.

Type of Work: Thesis (Doctorates > Ph.D.)
Award Type: Doctorates > Ph.D.
Supervisor(s):
Supervisor(s)EmailORCID
McCabe, ChristopherUNSPECIFIEDUNSPECIFIED
Smith, VickiUNSPECIFIEDUNSPECIFIED
Licence: All rights reserved
College/Faculty: Colleges (2008 onwards) > College of Medical & Dental Sciences
School or Department: Institute of Metabolism and Systems Research
Funders: None/not applicable
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
URI: http://etheses.bham.ac.uk/id/eprint/11613

Actions

Request a Correction Request a Correction
View Item View Item

Downloads

Downloads per month over past year